I. Vergote

发表

Size quantification of liver metastases in patients undergoing cancer treatment: reproducibility of one-, two-, and three-dimensional measurements determined with spiral CT.

E. Van Cutsem, L. V. Van Hoe, I. Vergote, 1997, Radiology.

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.

A. Howell, B. Erikstein, J. Robertson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients

I. Vergote, W. Schmitt, C. Gourley, 2021, Cancers.

Simple ultrasound‐based rules for the diagnosis of ovarian cancer

D. Jurkovic, T. Bourne, B. van Calster, 2008, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.

D. Katsaros, G. Yousef, A. Scorilas, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative diagnosis of ovarian tumors using Bayesian kernel‐based methods

J. Suykens, B. van Calster, D. Timmerman, 2007, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Genome-wide association study identifies a common variant associated with risk of endometrial cancer

M. Beckmann, P. Fasching, Jingmei Li, 2011, Nature Genetics.

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

D. Matei, J. Ledermann, J. Carmichael, 2012, The New England journal of medicine.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

D. Matei, J. Ledermann, J. Barrett, 2014, The Lancet. Oncology.

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing

P. D. Rijk, P. Loo, D. Lambrechts, 2011, Nature Biotechnology.

Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, PloS one.

Common variants at 19p13 are associated with susceptibility to ovarian cancer

A. Whittemore, D. Hernandez, L. Kiemeney, 2010, Nature Genetics.

Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer

Sebastian M. Armasu, Yurii B. Shvetsov, A. Whittemore, 2013, Nature Communications.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, A. Whittemore, 2015, Nature Genetics.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Lara E. Sucheston-Campbell, 2017, Nature Genetics.

Prognostic implications of lobular breast cancer histology: new insights from a single hospital cross-sectional study and SEER data.

P. Neven, M. Christiaens, H. Wildiers, 2014, Breast.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Ignace Vergote, Christian Marth, Sven Mahner, 2016, The New England journal of medicine.

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium

Theresia Thalhammer, Carsten Denkert, Georg Heinze, 2013, BMC Cancer.

PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS

Dong Liang, Jane E. Carpenter, Peter Kraft, 2016 .

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

V. Gebski, I. Vergote, S. Pignata, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer

Brooke L. Fridley, Hugo M. Horlings, Andrew E. Teschendorff, 2015, Genome Medicine.

Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second‐look laparotomy

I. Vergote, C. Tropé, M. Winderen, 1993 .

Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model.

J. Nesland, I. Vergote, C. Tropé, 1992, Gynecologic oncology.

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

G. MacBeath, H. Hirte, I. Vergote, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17 q 21 . 31

Sebastian M. Armasu, Yurii B. Shvetsov, A. Whittemore, 2013 .

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31

A. Whittemore, L. Kiemeney, M. Pike, 2013, Nature Communications.

Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.

T. Bourne, W. Collins, B. van Calster, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study

T. Bourne, B. van Calster, D. Timmerman, 2020, BMJ.

Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas.

T. Bourne, B. van Calster, D. Timmerman, 2016, The Lancet. Oncology.

Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors

T. Bourne, B. van Calster, D. Timmerman, 2015, Facts, views & vision in ObGyn.

Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study

D Timmerman, I Vergote, L Wynants, 2014, British Journal of Cancer.

Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies

J. Kaijser, C. Van Holsbeke, L. Valentin, 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol

T. Bourne, B. van Calster, D. Timmerman, 2012, BJOG : an international journal of obstetrics and gynaecology.

Improving the preoperative classification of adnexal masses as benign or malignant by second‐stage tests

D. Jurkovic, T. Bourne, B. De Moor, 2011, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

External Validation of Mathematical Models to Distinguish Between Benign and Malignant Adnexal Tumors: A Multicenter Study by the International Ovarian Tumor Analysis Group

Sabine Van Huffel, Dirk Timmerman, Enrico Ferrazzi, 2007, Clinical Cancer Research.

Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.

Sabine Van Huffel, Dirk Timmerman, Ignace Vergote, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

External Validation ofMathematical Models to Distinguish Between Benign andMalignant Adnexal Tumors : AMulticenter Study by the International Ovarian TumorAnalysis Group

S. Huffel, D. Timmerman, L. Valentin, 2007 .

Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience

D. Timmerman, T. Bourne, W. Collins, 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model.

W P Collins, D Timmerman, I Vergote, 1999, American journal of obstetrics and gynecology.

Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses

J Vandewalle, W P Collins, D Timmerman, 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group

T. Bourne, D. Timmerman, L. Valentin, 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Letters to the Editor

T. Bourne, W. Collins, D. Timmerman, 2001 .

Re: Mol et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001;80:162-7.

W P Collins, D Timmerman, I Vergote, 2001, Gynecologic oncology.

Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system.

I. Vergote, D. Gaffney, E. Petru, 2009, European journal of obstetrics, gynecology, and reproductive biology.

A new prognostic model for FIGO stage 1 epithelial ovarian cancer.

I. Vergote, M. Quinn, A. Proietto, 2007, Gynecologic oncology.

Role of Surgery in Ovarian Cancer: An Update

I. Vergote, 2004, Acta chirurgica Belgica.

Early ovarian cancer--time for a rethink on stage?

I. Vergote, F. Amant, 2004, Gynecologic oncology.

Adjuvant therapy for early staged (epithelial) cancer.

I. Vergote, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

I. Vergote, 2004, International Journal of Gynecologic Cancer.

Treatment of patients with early epithelial ovarian cancer

I. Vergote, B. Trimbos, 2003, Current opinion in oncology.

Controversies in surgery in ovarian cancer — what is its real role?

I. Vergote, 2003 .

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse.

V. Abeler, I. Vergote, E. Pettersen, 1993, American journal of obstetrics and gynecology.

Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer

I. Vergote, A. Coosemans, J. Ceusters, 2019, AntiCancer Research.

Ultrasound features of different histopathological subtypes of borderline ovarian tumors

D. Timmerman, I. Vergote, F. Smet, 2005, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Prognostic factors in 1545 patients with stage I invasive epithelial ovarian carcinoma: importance of degree of differentiation and cyst rupture in predicting relapse

Ignace Vergote, J. D. Brabanter, I. Vergote, 2001 .

Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women’s Cancers

Thomas E. Bartlett, B. Fridley, E. Goode, 2015, PloS one.

Positron Emission Tomography with FDG in the Detection of Peritoneal and Retroperitoneal Metastases of Ovarian Cancer

L. Mortelmans, L. Mortelmans, I. Vergote, 2003, Gynecologic and Obstetric Investigation.

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

I. Vergote, U. Matulonis, S. Lau, 2020, Gynecologic oncology.

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.

I. Vergote, C. Poole, T. Herzog, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The oestrogen receptor and its selective modulators in gynaecological and breast cancer.

P. Neven, I. Vergote, P. van Dam, 2000, European journal of cancer.

Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers

David N. Rider, L. Kiemeney, R. Vierkant, 2011, PloS one.

Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations

L. Kiemeney, P. Fasching, R. Vierkant, 2020, bioRxiv.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Oza, J. Ledermann, T. Park-Simon, 2021, The Lancet. Oncology.

ABCB 1 variation affects myelosuppression , progression-free 1 survival , and overall survival in paclitaxel / carboplatin-treated 2 ovarian cancer patients 3

I. Vergote, H. Gréen, N. Björn, 2018 .

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

I. Vergote, P. Vasey, A. du Bois, 2015, European journal of cancer.

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.

V. Gebski, I. Vergote, J. Sehouli, 2015, Gynecologic oncology.

The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.

P. Neven, I. Vergote, F. Amant, 2013, Gynecologic oncology.

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

V. Gebski, I. Vergote, C. Marth, 2012, British Journal of Cancer.

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group.

S. Loibl, N. Burchardi, I. Vergote, 2011, Gynecologic oncology.

Optimizing Management of Recurrent Epithelial Ovarian Cancer with Non–Platinum-Based Chemotherapy

I. Vergote, S. Pignata, G. Kristensen, 2008 .

Intraperitoneal chemotherapy in ovarian cancer remains experimental.

M. Gore, I. Vergote, A. du Bois, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

E. Eisenhauer, R. Kimmig, H. Hirte, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens.

H. Kitchener, D. Provencher, M. Friedlander, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

E. Eisenhauer, I. Vergote, A. du Bois, 2004, International Journal of Gynecologic Cancer.

The Impact of Hormone Receptor Status on the Clinical Efficacy of the New‐Generation Aromatase Inhibitors: A Review of Data from First‐Line Metastatic Disease Trials in Postmenopausal Women

A. Buzdar, I. Vergote, R. Sainsbury, 2004, The breast journal.

Tamoxifen, screening and new oestrogen receptor modulators.

P. Neven, I. Vergote, 2001, Best practice & research. Clinical obstetrics & gynaecology.

Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.

J. Robertson, M. Krzakowski, J. Bonneterre, 2000, European journal of cancer.

Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

A. Whittemore, M. Beckmann, P. Fasching, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

B. Monk, I. Vergote, S. Pignata, 2019, Gynecologic oncology.

Predicting the clinical behavior of ovarian cancer from gene expression profiles

N. Pochet, P. van Hummelen, B. De Moor, 2005, International Journal of Gynecologic Cancer.

Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.

David N. Rider, A. Whittemore, L. Kiemeney, 2014, Cancer research.

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.

P. van Damme, P. V. van Dam, I. Vergote, 1994, Journal of clinical pathology.

Cervical carcinoma: optimized local staging with intravaginal contrast-enhanced MR imaging--preliminary results.

L. V. Van Hoe, I. Vergote, R. Oyen, 1999, Radiology.

Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.

D. Timmerman, P. Neven, S. Van Huffel, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

M. Parmar, E. Eisenhauer, G. Rustin, 2010, International Journal of Gynecologic Cancer.

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

A. Reuss, B. Weber, I. Vergote, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

A. Reuss, B. Weber, I. Vergote, 2012, Journal of Clinical Oncology.

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

B. Karlan, J. Lubiński, J. Carmichael, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A scoring systemforimmunohistochemical staining: consensusreportofthetask force for basic research oftheEORTC-GCCG

P. Dam, I. Vergote, P. Diest, 1997 .

Leaders A scoring system for immunohistochemical staining : consensus report of the task force for basic research of the EORTC-GCCG

E. Berns, I. Vergote, S. Henzen‐Logmans, 2022 .

A Systematic Review of Estimating Breast Cancer Recurrence at the Population-Level with Administrative Data.

P. Neven, H. Wildiers, I. Vergote, 2020, Journal of the National Cancer Institute.

Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole

B. van Calster, D. Timmerman, P. Neven, 2010, Menopause.

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

E. van Limbergen, P. Neven, R. Paridaens, 2005, Journal of Clinical Pathology.

Breast cancer subtype and survival by parity and time since last birth

E. van Limbergen, P. Neven, H. Wildiers, 2018, Breast Cancer Research and Treatment.

Distribution of intraperitoneally injected microspheres labeled with the alpha-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in mice.

I. Vergote, C. Tropé, K. Nustad, 1992, Gynecologic oncology.

Surgery during chemotherapy and at relapse of ovarian cancer.

J. Berek, I. Vergote, C. Tropé, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome

Claudia C. Preston, David N. Rider, A. Whittemore, 2014, Cancer Immunology Research.

Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.

P. Neven, I. Vergote, F. Amant, 2005, Gynecologic oncology.

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer

R. Zeillinger, M. Svoboda, T. Thalhammer, 2018, Front. Pharmacol..

A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling

D. Lambrechts, B. Weynand, G. Floris, 2020, Cell Research.

A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling

D. Lambrechts, B. Weynand, G. Floris, 2020, Cell Research.

Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey

I. Vergote, I. McNeish, G. Aravantinos, 2020, International Journal of Gynecological Cancer.

Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model

I. Vergote, A. Coosemans, J. Ceusters, 2022, Pharmaceutics.

A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.

I. Vergote, D. Dodwell, 2005, Cancer treatment reviews.

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma

C. Osborne, A. Howell, J. Robertson, 2005, Cancer.

Logistic Regression and Artificial Neural Networks for Classification of Ovarian Tumors

S. Huffel, D. Timmerman, J. D. Brabanter, 2004 .

Should tamoxifen users be screened for endometrial lesions?

P. Neven, I. Vergote, 1998, The Lancet.

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.

P. Neven, I. Vergote, V. Jordan, 1996, European journal of cancer.

Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.

W. Foulkes, D. Lambrechts, O. Cussenot, 2021, European journal of cancer.

Classification of ovarian tumor using Bayesian least squares support vector machines

Sabine Van Huffel, Johan A. K. Suykens, Dirk Timmerman, 2003 .

Controversies regarding tamoxifen and uterine carcinoma.

P. Neven, I. Vergote, 1998, Current Opinion in Obstetrics and Gynecology.

Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?

E. van Limbergen, N. Pochet, P. Neven, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study

P. Neven, R. Paridaens, M. Christiaens, 2008, Breast Cancer Research and Treatment.

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.

A. Reuss, I. Vergote, A. Bamias, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How might we combine the information we know about a mass better ? The use of mathematical models to handle medical data

Sabine Van Huffel, Bart De Moor, Dirk Timmerman, 2000 .

Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review

C. Obasaju, I. Vergote, D. Miller, 2013 .

Experience with PlasmaJet™ in debulking surgery in 87 patients with advanced‐stage ovarian cancer

I. Vergote, T. Van Gorp, Sileny N. Han, 2021, Journal of surgical oncology.

Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors

I. Vergote, C. Leamon, 2015, Therapeutic advances in medical oncology.

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.

M. Gore, H. Gabra, I. Vergote, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up.

J. Menten, B. van Calster, P. Neven, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection and diagnosis

P. Neven, C. Denkert, M. Dietel, 2012 .

A randomized trial of adjuvant progestagen in early endometrial cancer

V. Abeler, I. Vergote, P. Kolstad, 1989, Cancer.

Endometriosis and the development of malignant tumours of the pelvis. A review of literature.

P. Neven, I. Vergote, F. Amant, 2004, Best practice & research. Clinical obstetrics & gynaecology.

The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers.

P. Neven, M. Christiaens, H. Wildiers, 2013, Breast.

Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer

I. Vergote, I. Vergote, A. Papanikolaou, 2006, Archives of Gynecology and Obstetrics.

Laparoscopy in Patients with Endometrial Cancer

I. Vergote, J. Decloedt, 2003 .

Laparoscopy in gynaecologic oncology: a review.

I. Vergote, I. Vergote, J. Decloedt, 1999, Critical reviews in oncology/hematology.

Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen.

D. Timmerman, P. Neven, I. Vergote, 1998, Cancer research.

Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer.

L. V. Van Hoe, I. Vergote, S. Gryspeerdt, 1998, European journal of gynaecological oncology.

Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.

H. Comber, J. Rashbass, I. Vergote, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.

M. Buyse, I. Vergote, H. Bjermo, 2019, Gynecologic oncology.

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer

I. Vergote, S. Pignata, J. Bryce, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.

G. Rustin, I. Vergote, J. Bendell, 2017, Gynecologic oncology.

Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.

I. Vergote, S. Pignata, J. Bryce, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

G. Hall, V. Ostapenko, B. Melichar, 2017, International Journal of Gynecologic Cancer.

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.

Jae-Weon Kim, B. Monk, I. Vergote, 2015, Gynecologic oncology.

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.

I. Vergote, F. Amant, A. Laenen, 2015, Gynecologic oncology.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study

R. Zeillinger, I. Vergote, N. Concin, 2016, Tumor Biology.

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.

R. Wenham, I. Vergote, L. Dirix, 2014, Gynecologic oncology.

Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

I. Vergote, G. Kristensen, K. Lindemann, 2014, BMC Cancer.

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

I. Vergote, H. Chalchal, E. Pujade-Lauraine, 2012, British Journal of Cancer.

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

B. Karlan, E. Rasmussen, I. Vergote, 2012, Cancer Chemotherapy and Pharmacology.

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

E. Eisenhauer, A. Oza, D. Provencher, 2010, Journal of the National Cancer Institute.

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.

E. Eisenhauer, I. Vergote, G. Kristensen, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas

I. Vergote, C. Tropé, J. Kærn, 2004, Cancer Chemotherapy and Pharmacology.

Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study

K. Kinzler, B. Vogelstein, L. Diaz, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.

I. Vergote, L. Gianni, C. Poole, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium—OVCAD

R. Zeillinger, I. Vergote, P. Speiser, 2012, International Journal of Gynecologic Cancer.

Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)

A. Berjón, I. Vergote, P. Dundr, 2020, Cancers.

Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.

T. Bourne, B. van Calster, D. Timmerman, 2016, American Journal of Obstetrics and Gynecology.

Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al

D. Timmerman, I. Vergote, N. Concin, 2021, International Journal of Gynecological Cancer.

Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer

D. Timmerman, I. Vergote, A. Coosemans, 2021, Cancers.

Independent Test Set Performance in the Prediction of Early Relapse in Ovarian Cancer with Gene Expression Profiles

N. Pochet, B. De Moor, D. Timmerman, 2005, Clinical Cancer Research.

AUC 2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol , a sensitizer of platinum cytotoxicity : the phase III OVATUREmulticenter randomized study

M. Gore, H. Gabra, I. Vergote, 2013 .

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

E. Eisenhauer, I. Vergote, A. du Bois, 2004, International Journal of Gynecologic Cancer.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

Surgery during chemotherapy and at relapse of ovarian cancer

J. Berek, I. Vergote, C. Tropé, 1999 .

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

D. Provencher, M. Birrer, I. Vergote, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen.

T. Bourne, W. Collins, D. Timmerman, 1998, American journal of obstetrics and gynecology.

Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab.

I. Vergote, C. Marth, G. Daxenbichler, 2007, Gynecologic oncology.

Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case Report.

I. Vergote, P. Moerman, A. Vanderstichele, 2017, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)

E. Eisenhauer, G. Rustin, I. Vergote, 2005 .

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Morphology and tumour‐infiltrating lymphocytes in high‐stage, high‐grade serous ovarian carcinoma correlated with long‐term survival

C. Denkert, I. Vergote, S. Wienert, 2018, Histopathology.

Title Obesity and survival among women with ovarian cancer : Results from the Ovarian Cancer Association Consortium Permalink

A. Whittemore, P. Fasching, R. Vierkant, 2015 .

Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium

A. Whittemore, P. Fasching, R. Vierkant, 2015, British Journal of Cancer.

Safety and dose modification for patients receiving niraparib

J. Ledermann, J. Berek, I. Vergote, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.

B. van Calster, D. Timmerman, P. Neven, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study

P. Neven, R. Paridaens, H. Wildiers, 2018, Breast Cancer Research and Treatment.

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium

R. Zeillinger, I. Vergote, P. Speiser, 2013, Journal of Ovarian Research.

Role of adnexectomy in the surgical treatment of cervical adenocarcinoma

I. Vergote, F. Amant, K. Van Calsteren, 2004, International Journal of Gynecologic Cancer.

Observational BGOG Study Of The Results Of Robot-Assisted Laparoscopy In 166 Patients With FiGO 2009 Stage Ia1- Ib1 Cervical Cancer.

I. Vergote, F. Goffin, K. Traen, 2021, Journal of minimally invasive gynecology.

Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial.

S. Marnitz, I. Vergote, D. Cibula, 2020, European journal of cancer.

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

I. Vergote, W. Cliby, R. Coleman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life

E. Eisenhauer, M. Brundage, D. Tu, 2016, Supportive Care in Cancer.

Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.

I. Vergote, F. Amant, G. Kristensen, 2011, European journal of cancer.

Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer.

I. Vergote, F. Amant, C. Tropé, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.

I. Vergote, A. Jakobsen, K. Bertelsen, 2003, Gynecologic oncology.

The role of interval debulking surgery in ovarian cancer

I. Vergote, M. Burg, 2003, Current oncology reports.

First‐line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin

E. Eisenhauer, I. Vergote, G. Kristensen, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin

E. Eisenhauer, I. Vergote, G. Kristensen, 2003, International Journal of Gynecologic Cancer.

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International Journal of Gynecologic Cancer.

Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.

E. Eisenhauer, A. Oza, I. Vergote, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cervical neoplasia during pregnancy: diagnosis, management and prognosis.

I. Vergote, F. Amant, K. Van Calsteren, 2005, Best practice & research. Clinical obstetrics & gynaecology.

Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.

P. Neven, R. Paridaens, M. Christiaens, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related

P. Neven, R. Paridaens, M. Christiaens, 2005, Breast Cancer Research and Treatment.

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

P. Altevogt, I. Vergote, M. Netzer, 2013, Journal of the National Cancer Institute.

Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.

I. Vergote, A. du Bois, T. Baert, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

Jae-Weon Kim, C. Schade-Brittinger, A. Reuss, 2019, The New England journal of medicine.

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.

A. Reuss, I. Vergote, J. Sehouli, 2019, Gynecologic oncology.

Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

I. Vergote, F. Amant, F. Heitz, 2013, Gynecologic oncology.

Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.

G. Rustin, I. Vergote, G. Kristensen, 2013, Gynecologic oncology.

Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.

I. Vergote, F. Heitz, P. Harter, 2013, Gynecologic oncology.

Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO

A. Reuss, I. Vergote, J. Sehouli, 2010, International Journal of Gynecologic Cancer.

Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy

J. Robertson, I. Vergote, L. Mauriac, 2003, Breast Cancer Research and Treatment.

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).

B. Monk, I. Vergote, S. Pignata, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.

P. Neven, I. Vergote, F. Amant, 2008, The oncologist.

Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.

M. Nooij, I. Vergote, D. Wagener, 2001, European Journal of Gynaecological Oncology.

Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity; ABRAX (ABandoning RAd hyst in cerviX cancer)

L. Dušek, I. Vergote, D. Cibula, 2019, International Journal of Gynecological Cancer.

A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?

I. Vergote, A. Coosemans, T. Baert, 2015, Facts, views & vision in ObGyn.

Dendritic cell-based immunotherapy in ovarian cancer

I. Vergote, A. Coosemans, S. V. Van Gool, 2013, Oncoimmunology.

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

D. Matei, J. Ledermann, C. Scott, 2016, British Journal of Cancer.

Port‐site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma

P. Neven, I. Vergote, F. Amant, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced?

P. V. van Dam, W. Tjalma, I. Vergote, 1999, American journal of obstetrics and gynecology.

Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohort.

I. Vergote, A. Laenen, F. Goffin, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, A. Whittemore, 2013, Human Genetics.

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

M. Pike, M. Beckmann, P. Fasching, 2021, Virchows Archiv.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

B. Monk, A. Tinker, A. Oza, 2017 .

Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study.

P. Hall, S. Chanock, M. García-Closas, 2011, Carcinogenesis.

Does the Stellate Ganglion Block Reduce Severe Hot Flushes and Sleep Disturbances in Breast Cancer Patients

J. Menten, P. Neven, R. Paridaens, 2009 .

Radio‐immunotargeting in experimental animal models of intraperitoneal cancer

I. Vergote, K. Nustad, L. D. De Vos, 1992, Acta obstetricia et gynecologica Scandinavica. Supplement.

Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials

J. Robertson, I. Vergote, 2004, British Journal of Cancer.

Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients

E. van Limbergen, D. Timmerman, P. Neven, 2004, Anti-cancer drugs.

HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?

I. Vergote, J. Sehouli, L. Chiva, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CA125 in peritoneal fluid of ovarian cancer patients.

I. Vergote, O. Børmer, M. Onsrud, 1992, Gynecologic oncology.

Indications, techniques and outcomes for pelvic exenteration in gynecological malignancy

I. Vergote, A. D'Hoore, S. Joniau, 2014, Current opinion in oncology.

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium

Francesmary Modugno, James Paul, Honglin Song, 2015 .

Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.

Dong Liang, Thilo Dörk, Natalia Bogdanova, 2014, Molecular nutrition & food research.

Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

D. Matei, J. Carmichael, C. Watkins, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy

M. Piccart, I. Vergote, P. Willemse, 2003, International Journal of Gynecologic Cancer.

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

F. Marmé, I. Vergote, S. Pignata, 2019, The New England journal of medicine.

A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral Metastases

A. Howell, J. Robertson, I. Vergote, 2003, Breast Cancer Research and Treatment.

PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).

J. Brenton, H. Gabra, I. Vergote, 2016 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial

B. van Calster, P. Neven, S. Van Huffel, 2018, Clinical Cancer Research.

Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

S. Huffel, D. Timmerman, P. Neven, 2009, Breast Cancer Research and Treatment.

In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.

B. van Calster, V. Van Belle, P. Neven, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Wei Lu, Wei Zheng, Mads Thomassen, 2013, Nature Genetics.

Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.

P. Neven, I. Vergote, F. Amant, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials

A. Howell, A. Buzdar, I. Vergote, 2004 .

Report of an Early Stopped Randomized Trial Comparing Cisplatin vs. Cisplatin/Ifosfamide/ 5-Fluorouracil in Recurrent Cervical Cancer

I. Vergote, A. Jakobsen, I. Cadron, 2005, Gynecologic and Obstetric Investigation.

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

E. Eisenhauer, G. Rustin, I. Vergote, 2005, Journal of the National Cancer Institute.

Advanced epithelial ovarian cancer

M. Parmar, E. Eisenhauer, M. Gore, 1999 .

Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).

D. Smith, B. Sikic, I. Vergote, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study

F. Marmé, I. Vergote, A. Santoro, 2014, Medical Oncology.

Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer

B. van Calster, D. Timmerman, P. Neven, 2022, NPJ genomic medicine.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Combining conventional therapy with immunotherapy: A risky business?

J. Ledermann, L. Boon, I. Vergote, 2019, European journal of cancer.

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium

H. Gabra, I. Vergote, J. Sehouli, 2022, Annals of Surgical Oncology.

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.

P. Fasching, F. Marmé, I. Vergote, 2022, European journal of cancer.

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.

I. Vergote, Jung-Min Lee, N. Colombo, 2022, Gynecologic oncology.

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

E. Kohn, V. Gebski, A. Reuss, 2022, The Lancet. Oncology.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).

D. Matei, J. Ledermann, C. Scott, 2013 .

Immunotherapy in rare ovarian cancer

I. Vergote, E. Van Nieuwenhuysen, T. Laga, 2021, Current opinion in oncology.

randomization Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study

A. Whittemore, M. Beckmann, A. Hein, 2016 .

Intraperitoneal alpha therapy with 224Ra-labeled microparticles combined with chemotherapy in an ovarian cancer mouse model

I. Vergote, A. Coosemans, J. Ceusters, 2022, Frontiers in Medicine.

Improving outcome in the first-line management of advanced ovarian cancer

P. Neven, I. Vergote, F. Amant, 2007 .

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

I. Vergote, W. Cliby, R. Coleman, 2016, Gynecologic oncology.

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

V. Gebski, M. Dimopoulos, I. Vergote, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG).

V. Gebski, I. Vergote, S. Pignata, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy

M. Piccart, I. Vergote, P. Willemse, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature.

D. Timmerman, I. Vergote, P. Moerman, 1995, Gynecologic oncology.

An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors.

L. Galluzzi, J. Galon, I. Vergote, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies

I. Vergote, A. Coosemans, S. V. Van Gool, 2014, Expert review of clinical immunology.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Ignace Vergote, Beth Y Karlan, Christian Marth, 2016, Gynecologic oncology.

Incidence and management of edema associated with trebananib (AMG 386).

B. Monk, B. Karlan, I. Vergote, 2013, Gynecologic oncology.

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

D. Provencher, H. Hirte, I. Vergote, 2012, The Lancet. Oncology.

NEOADJUVANT CHEMOTHERAPY VERSUS PRIMARY DEBULKING SURGERY IN ADVANCED OVARIAN CANCER

I. Vergote, M. V. Gramberen, J. Decloedt, 2003, International Journal of Gynecologic Cancer.

Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

H. Putter, B. Monk, D. Provencher, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy

P. Bossuyt, G. Kenter, I. Vergote, 2018, International Journal of Gynecologic Cancer.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

D. Provencher, J. Ledermann, M. Birrer, 2018 .

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.

R. Wenham, I. Vergote, J. Fiorica, 2019, Gynecologic oncology.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial

B. Monk, B. Karlan, A. Oza, 2014 .

Laparoscopic hysterectomy for early endometrial cancer.

P. Neven, I. Vergote, F. Amant, 2010, The Lancet. Oncology.

Positive DESKTOP and Tian Scores Systems Are Adequate to Predict Optimal (R0) Secondary Debulking Surgery in Ovarian Cancer, But a Negative Score Does Not Preclude Secondary Surgery

I. Vergote, A. Laenen, Sileny N. Han, 2018, International Journal of Gynecologic Cancer.

Hexamethylmelamine as second‐line therapy in platin‐resistant ovarian cancer

I. Vergote, C. Tropé, M. Scheistrøen, 1993, Gynecologic oncology.

Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG

E. Eisenhauer, R. Kimmig, H. Hirte, 2004 .

E. Eisenhauer, R. Kimmig, H. Hirte, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

M. Parmar, V. Torri, I. Vergote, 2003, Journal of the National Cancer Institute.

Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery

M. Parmar, Torri, I. Vergote, 2001 .

Evaluation of serum CA 125 levels in the monitoring of ovarian cancer

V. Abeler, I. Vergote, O. Børmer, 1988, American journal of obstetrics and gynecology.

An international multicentre Phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/Paclitaxel + Platinum containing chemotherapy (CT)

M. Carey, L. Seymour, H. Hirte, 2001 .

Lymphadenectomy in endometrial cancer : when

P. Neven, I. Vergote, F. Amant, 2010 .

'State of the art' of radical hysterectomy; current practice in European oncology centres.

M. Franchi, I. Vergote, J. Trimbos, 2004, European journal of cancer.

The “Definitive” Trial of Surgical Cytoreduction in Advanced-Stage Ovarian Cancer

J. Donovan, D. Chi, I. Vergote, 2013, International Journal of Gynecologic Cancer.

Management of Recurrent Endometrioid Endometrial Carcinoma: An Overview

I. Vergote, H. V. van Doorn, C. Burger, 2009, International Journal of Gynecologic Cancer.

Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study

I. Vergote, K. Steffensen, C. Marth, 2013, International Journal of Gynecologic Cancer.

Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.

D. Berton, I. Vergote, S. Pignata, 2020 .

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

A. Oza, M. Birrer, I. Vergote, 2018, Future oncology.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

I. Vergote, I. McNeish, S. Pignata, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

M. Parmar, M. Parmar, G. Jayson, 2018, The Lancet. Oncology.

What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients.

I. Vergote, J. Sehouli, F. Joly, 2017 .

Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

B. Monk, B. Karlan, A. Oza, 2015 .

Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look.

I. Vergote, C. Tropé, J. Kærn, 1992 .

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

I. Vergote, S. Pignata, R. Coleman, 2019, Gynecologic oncology.

Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

G. Rustin, I. Vergote, C. Pippitt, 2010 .

SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer

P. Rolland, F. Guyon, B. Chiofalo, 2022, Annals of Surgical Oncology.

Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.

I. Vergote, 2002, European Journal of Cancer.

Value of positron emission tomography of the para-aortic lymph nodes in cervical carcinoma stage IB2-IIIB.

E. van Limbergen, P. Neven, F. Mottaghy, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ERBB-2 gene overexpression and amplification in uterine sarcomas.

I. Vergote, M. Debiec‐Rychter, F. Amant, 2004, Gynecologic oncology.

Second-look Laparoscopy in Patients with Ovarian Cancer

I. Vergote, J. Decloedt, 2003 .

Interval debulking surgery: an alternative for primary surgical debulking?

P. V. van Dam, W. Tjalma, I. Vergote, 2000, Seminars in surgical oncology.

Reply to B. Freidlin et al.

A. Jimeno, I. Vergote, C. Coens, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015

A. Reuss, J. Ledermann, R. Glasspool, 2015, International Journal of Gynecologic Cancer.

Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials

I. Vergote, J. Bryce, A. du Bois, 2013, International Journal of Gynecologic Cancer.

European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies

J. Ledermann, I. Vergote, G. Tulunay, 2010, International Journal of Gynecologic Cancer.

Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.

V. Gebski, I. Vergote, S. Pignata, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZD9331 in combination with topotecan: phase I and II experience

A. Benson, I. Vergote, E. Poplin, 2003, Anti-cancer drugs.

Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.

V. Abeler, I. Vergote, C. Tropé, 1993, Gynecologic oncology.

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer

R. Rouzier, I. Vergote, F. Landoni, 2017, International Journal of Gynecologic Cancer.

Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.

I. Vergote, K. Nustad, R. Larsen, 1995, Gynecologic Oncology.

211At-labelling of polymer particles for radiotherapy : synthesis, purification and stability

I. Vergote, K. Nustad, R. Larsen, 1993 .

Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.

B. van Calster, D. Timmerman, P. Neven, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines

I. Vergote, L. Sojka, A. Coosemans, 2022, Oncoimmunology.

A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours

J. Hainsworth, I. Vergote, J. Janssens, 2003, Anti-cancer drugs.

Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.

A. Whittemore, D. Hernandez, L. Kiemeney, 2016, Nature genetics.

Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors

S. Huffel, P. Neven, V. Belle, 2009, Breast Cancer Research and Treatment.

Edinburgh Explorer Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients

I. Vergote, W. Schmitt, C. Gourley, 2021 .

Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging

D. Timmerman, P. Neven, R. Paridaens, 2007, Breast Cancer Research and Treatment.

The influence of body composition and hormone replacement therapy (HRT) on progesterone receptor (PR) expression in postmenopausal women with an oestrogen receptor (ER)-positive breast cancer

B. Moor, N. Pochet, P. Neven, 2006 .

ICI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women — prospective combined analysis of two multicenter trials

M. Ellis, A. Howell, J. Robertson, 2001 .

Progesterone receptor gene variants and risk of endometrial cancer.

K. Czene, P. Hall, T. Rebbeck, 2011, Carcinogenesis.

Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort

J. Menten, P. Neven, H. Wildiers, 2021, Journal of Cancer Research and Clinical Oncology.

Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer: Results From a Safety Lead-in Study

T. Bauknecht, I. Vergote, F. Amant, 2009, International Journal of Gynecologic Cancer.

Randomized phase III study comparing paclical-carboplatin with paclitaxel-carboplatin in patients with recurrent platinum-sensitive epithelial ovarian cancer.

I. Vergote, M. Lichinitser, A. Brize, 2015 .

High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report

I. Vergote, M. Debiec‐Rychter, F. Amant, 2010, Journal of medical case reports.

Early response monitoring with FDG-PET in a phase I study in metastatic breast cancer

P. Dupont, L. Mortelmans, I. Vergote, 1999 .

Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC).

B. Weber, I. Vergote, J. Šufliarský, 2013 .

PGF2α Levels in breast cancer tissue

I. Vergote, A. Herman, G. Laekeman, 1984 .

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Lara E Sucheston-Campbell, A. Whittemore, M. Beckmann, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium

E. Obermayr, R. Zeillinger, I. Vergote, 2021, Cancers.

Prognostic value of prostaglandin F2 alpha concentrations in breast carcinoma.

P. V. van Dam, I. Vergote, A. Herman, 1989, Journal of clinical pathology.

The prognostic and predictive value of the progesterone receptor in women with an oestrogen receptor positive breast cancer

P. Neven, R. Paridaens, M. Christiaens, 2004 .

Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide.

P. Neven, I. Vergote, F. Amant, 2012, Gynecologic oncology.

Ovarian cancer and the immune system

I. Vergote, A. Coosemans, T. Baert, 2017, Gynecologic oncology reports.

Prostacyclin and thromboxane in benign and malignant breast tumours.

I. Vergote, A. Herman, G. Laekeman, 1986, British Journal of Cancer.

CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma.

V. Abeler, I. Vergote, C. Tropé, 1992, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort

D. Bodurka, I. Vergote, R. Coleman, 2022, International Journal of Gynecological Cancer.

EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.

I. Vergote, I. Lowy, C. Ivanescu, 2022, European journal of cancer.

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

J. Robertson, M. Krzakowski, J. Bonneterre, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Images in clinical medicine. Tamoxifen-induced endometrial polyp.

D. Timmerman, I. Vergote, 1996, The New England journal of medicine.

Surgical and systemic management of endometrial cancer: an international survey

S. Kehoe, I. Vergote, D. Miller, 2015, Archives of Gynecology and Obstetrics.

A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer

Bram Boeckx, Georg Heinze, Ignace Vergote, 2017, Clinical Cancer Research.

Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer

James Paul, Ignace Vergote, Jalid Sehouli, 2016, Clinical Cancer Research.

EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA)

G. Kenter, I. Vergote, F. Amant, 2008 .

Evaluation of T2-W MR imaging and diffusion-weighted imaging for the early post-treatment local response assessment of patients treated conservatively for cervical cancer: a multicentre study

E. van Limbergen, J. Stoker, I. Vergote, 2018, European Radiology.

Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.

F. Marmé, I. Vergote, I. Ray-Coquard, 2022, European journal of cancer.

8050 POSTER Cost-effectiveness of Trabectedin in Combination With Pegylated Liposomal Doxorubicin Hydrochloride for the Treatment of Women With Relapsed Platinum-sensitive Ovarian Cancer in the UK -Analysis Based on the Final Survival Data

M. Gore, I. Vergote, N. Colombo, 2011 .

Pelvic Exenterations for Gynecological Malignancies: A Study of 36 Cases

E. van Limbergen, B. van Calster, I. Vergote, 2012, International Journal of Gynecologic Cancer.

Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting.

P. Neven, D. Lambrechts, R. Paridaens, 2016 .

Robot-Assisted Radical Hysterectomy in Cervical Carcinoma: The Belgian Experience

I. Vergote, K. Leunen, F. Goffin, 2015, International Journal of Gynecologic Cancer.

ABCB1 Variation Affects Myelosuppression, Progression‐free Survival and Overall Survival in Paclitaxel/Carboplatin‐treated Ovarian Cancer Patients

I. Vergote, H. Gréen, N. Björn, 2018, Basic & clinical pharmacology & toxicology.

Combined modality adjuvant therapy for high-risk endometrial cancer.

P. Neven, I. Vergote, A. Vanderstichele, 2016, The Lancet. Oncology.

EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials

E. Berns, A. Jimeno, D. Katsaros, 2012 .

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.

I. Vergote, J. Huober, I. Ray-Coquard, 2011, Gynecologic oncology.

Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy

I. Vergote, F. Amant, P. Moerman, 2008, Acta obstetricia et gynecologica Scandinavica.

Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer

I. Vergote, L. Chiva, P. Harter, 2019, Cancer.

Is There a Role for Intraperitoneal Chemotherapy, Including HIPEC, in the Management of Ovarian Cancer?

I. Vergote, L. Chiva, P. Harter, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology , early and advanced stages , borderline tumours and recurrent disease

J. Ledermann, I. Vergote, I. McNeish, 2019 .

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.

D. Timmerman, J. Ledermann, R. Glasspool, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk

Yurii B. Shvetsov, Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, 2015, Genetic epidemiology.

Epithelial ovarian cancer

A. Oza, S. Lheureux, I. Vergote, 2019, The Lancet.

Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review

D. Timmerman, I. Vergote, T. Van Gorp, 2019, Journal of Ovarian Research.

High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification

D. Lambrechts, I. Vergote, A. Coosemans, 2021, Genome Medicine.

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.

D. Provencher, J. Ledermann, M. Birrer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium

Georg Heinze, Ignace Vergote, Jalid Sehouli, 2012, Cancer science.

The utility of proteomics in gynecologic cancers

I. Vergote, T. Van Gorp, I. Cadron, 2011, Current opinion in obstetrics & gynecology.

Placental alkaline phosphatase as a tumor marker in ovarian cancer

I. Vergote, K. Nustad, M. Onsrud, 1987, Obstetrics and gynecology.

Dysgerminoma of the ovary in association with XY gonadal dysgenesis.

I. Vergote, P. Buytaert, D. Becquart, 1983, European journal of obstetrics, gynecology, and reproductive biology.

Human Chorionic Gonadotropin Regression Curves after Partial or Complete Molar Pregnancy in Flanders: Are They Different from Regression Curves from the Eighties?

I. Vergote, P. Moerman, Sileny N. Han, 2017, Gynecologic and Obstetric Investigation.

Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease.

P. Delvenne, I. Vergote, E. Marbaix, 2020, European journal of obstetrics, gynecology, and reproductive biology.

[Belgian register and reference centers for gestational trophoblastic diseases].

P. Delvenne, M. Timmermans, I. Vergote, 2015, Revue medicale de Liege.

Endodermal sinus tumor of the vulva: successfully treated with high-dose chemotherapy.

I. Vergote, P. Moerman, J. Maertens, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Endodermal sinus tumor of the vulva: successfully treated with high-dose chemotherapy

I. Vergote, P. Moerman, J. Maertens, 2004, International Journal of Gynecologic Cancer.

Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.

I. Vergote, A. Coosemans, A. Laenen, 2018, Gynecologic oncology.

Anaplastic nodules in an ovarian mucinous tumor. Case report and literature review.

D. Timmerman, I. Vergote, P. Moerman, 1998, European journal of gynaecological oncology.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS

Bart De Moor, Anneleen Daemen, Ignace Vergote, 2012, Proteome Science.

The genetic landscape of 87 ovarian germ cell tumors.

P. Neven, D. Lambrechts, I. Vergote, 2018, Gynecologic oncology.

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.

M. Franchi, I. Vergote, C. Coens, 2003, Journal of the National Cancer Institute.

International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma.

M. Parmar, V. Torri, I. Vergote, 2003, Journal of the National Cancer Institute.

Evaluation of serum CA 125 levels in the monitoring of ovarian cancer

V. Abeler, I. Vergote, O. Børmer, 1987, American journal of obstetrics and gynecology.

Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study.

J B Vermorken, E Wiltshaw, I. Vergote, 1999, European journal of cancer.

A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

I. Vergote, S. Pignata, F. Amant, 2011, Cancer Chemotherapy and Pharmacology.

Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management

H. Wildiers, I. Vergote, P. Vermeulen, 2015, Breast Cancer Research.

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

Peter Kraft, Todd L Edwards, Nazneen Rahman, 2016, Cancer discovery.

Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening

D. Timmerman, D. Lambrechts, I. Vergote, 2019, Nature Cell Biology.

Clinical management of uterine sarcomas.

D. Timmerman, I. Vergote, M. Debiec‐Rychter, 2009, The Lancet. Oncology.

Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.

Ignace Vergote, Jalid Sehouli, Ioana Braicu, 2014, European journal of cancer.

Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.

Raffi Tonikian, I. Vergote, T. French, 2022, European journal of cancer.

Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.

D. Lambrechts, I. Vergote, A. Vanderstichele, 2017, European journal of cancer.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

James X. Sun, A. Oza, D. Provencher, 2017, The Lancet.

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

D. Matei, J. Ledermann, C. Scott, 2016, The Lancet. Oncology.

Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Werner Meier, Ignace Vergote, Philipp Harter, 2016, Cancer.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

D. Matei, J. Ledermann, J. Barrett, 2014 .

Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion

I. Vergote, V. Bours, K. van de Vijver, 2022, Facts, views & vision in ObGyn.

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

R. Zeillinger, I. Vergote, S. Darb-Esfahani, 2014, European journal of cancer.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

B. Monk, K. Jardon, I. Vergote, 2019, The New England journal of medicine.

Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation.

P. Altevogt, R. Zeillinger, T. Hielscher, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Trials in Recurrent Ovarian Cancer

D. Alberts, A. Tinker, E. Trimble, 2011, International Journal of Gynecologic Cancer.

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

B. Monk, I. Vergote, A. Makhson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer

P. Zimmermann, M. Jaritz, R. Zeillinger, 2016, BMC Genomics.

Orientation of Preclinical Research in Ovarian Cancer

P. Agostinis, I. Vergote, A. Coosemans, 2017, International Journal of Gynecologic Cancer.

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.

M. Parmar, E. Eisenhauer, G. Rustin, 2000, Journal of the National Cancer Institute.

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Joshy George, Keitaro Matsuo, Ignace Vergote, 2014, Journal of the National Cancer Institute.

Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer

I. Vergote, A. Coosemans, T. Baert, 2019, Frontiers in Immunology.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma

R. Bernards, J. Brenton, A. V. D. Van Der Zee, 2018, Clinical Cancer Research.

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Yurii B. Shvetsov, M. Pike, A. Talhouk, 2022, Cancer.

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer

R. Kimmig, E. Obermayr, R. Zeillinger, 2020, Cancers.

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer

R. Zeillinger, T. Thalhammer, I. Vergote, 2017, Oncology letters.

Genome-wide significant risk associations for mucinous ovarian carcinoma

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Genetics.

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium

C. Denkert, R. Zeillinger, I. Vergote, 2014, Molecular Cancer.

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

R. Zeillinger, I. Vergote, H. Ulmer, 2011, British Journal of Cancer.

Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium

L. Kiemeney, R. Vierkant, T. Sellers, 2011, PloS one.

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).

P. V. van Diest, E. Berns, M. Vijver, 2006, European journal of cancer.

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.

I. Vergote, N. Concin, M. Mirza, 2019, Gynecologic oncology.

Shared genetics underlying epidemiological association between endometriosis and ovarian cancer.

A. Whittemore, A. Morris, L. Kiemeney, 2015, Human molecular genetics.

Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2016, Oncotarget.

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers

Ignace Vergote, Luc Y Dirix, P. V. van Dam, 2012, Breast Cancer Research.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

B. Monk, B. Karlan, A. Oza, 2014, The Lancet. Oncology.

A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: Evaluation of the analytical performance.

I. Vergote, S. Pignata, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses

D. Timmerman, P. Neven, D. Lambrechts, 2016, Clinical Cancer Research.

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial

D. Berton, I. Vergote, S. Pignata, 2021, Gynecologic Oncology.

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial

D. Berton, I. Vergote, S. Pignata, 2023, JCO precision oncology.

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

I. Vergote, I. Ray-Coquard, F. Heitz, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data

R. Zeillinger, I. Vergote, N. Concin, 2012, International Journal of Gynecologic Cancer.

Randomized controlled phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – AGO DESKTOP III/ENGOT ov20

A. Reuss, F. Guyon, J. Kim, 2017, Geburtshilfe und Frauenheilkunde.

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.

C. V. van Asperen, I. Vergote, D. Stoppa-Lyonnet, 2016, European journal of cancer.

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes

I. Vergote, V. Bours, B. Blaumeiser, 2016, Facts, views & vision in ObGyn.

Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2018, British Journal of Cancer.

Assessing the genetic architecture of epithelial ovarian cancer histological subtypes

A. Whittemore, L. Kiemeney, M. Beckmann, 2016, Human Genetics.

ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

S. Marnitz, J. Ledermann, I. Vergote, 2021, Virchows Archiv.

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

Cyrus Chargari, S. Marnitz, J. Ledermann, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Cyrus Chargari, S. Marnitz, J. Ledermann, 2020, International Journal of Gynecological Cancer.

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.

M. Piccart, M. Nooij, M. Franchi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary

I. Vergote, C. Tropé, G. Kristensen, 1992, International Journal of Gynecologic Cancer.

Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern

V. Abeler, I. Vergote, C. Tropé, 1996, Cancer.

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

E. Berns, A. Jimeno, D. Lambrechts, 2015, Targeted Oncology.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup

A. Jimeno, D. Katsaros, I. Vergote, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.

V. Gebski, R. Simes, R. Simes, 2011, Journal of the National Cancer Institute.

Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

Brooke L. Fridley, M. Eileen Dolan, Soma Das, 2011, Clinical Cancer Research.

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

G. Kenter, I. Vergote, F. Amant, 2010, The New England journal of medicine.

A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.

I. Vergote, C. Kaiser, J. Sehouli, 2009, European journal of cancer.

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.

E. Berns, D. Lambrechts, R. Zeillinger, 2016, European journal of cancer.

The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment.

I Vergote, P. Neven, D. Lambrechts, 2010, Gynecologic oncology.

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer

M. Widschwendter, E. Schuuring, A. V. D. Van Der Zee, 2017, BMC Medicine.

Malignant trophoblastic disease following a twin pregnancy consisting of a complete hydatiform mole and a normal fetus and placenta. A case report.

I. Vergote, M. Hanssens, G. Page, 1999, European journal of gynaecological oncology.

Second case of uterine mesonephric adenocarcinoma.

I. Vergote, F. Amant, P. Moerman, 2006, International Journal of Gynecological Cancer.

Clinicopathologic markers of uterine leiomyosarcoma originating from smooth muscle tumors of low malignancy

I. Vergote, G. Tulunay, M. Debiec‐Rychter, 2005 .

Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.

E. van Limbergen, M. de Brabandere, A. Nulens, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course

S. Seys, I. Vergote, A. Coosemans, 2015, Oncoimmunology.

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

I Vergote, P. V. van Diest, E. Berns, 1997, Journal of clinical pathology.

A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples

P. Neven, P. V. van Dam, G. G. Van den Eynden, 2014, PloS one.

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium

E. Obermayr, R. Zeillinger, I. Vergote, 2017, Oncotarget.

Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.

Jae-Weon Kim, V. Gebski, A. Oza, 2020, European journal of cancer.

Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

I. Vergote, J. Keck, C. Runowicz, 2010, International Journal of Gynecologic Cancer.

Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation.

A. Hagemeijer, I. Vergote, M. Debiec‐Rychter, 2003, Gynecologic oncology.

First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynaecological Cancer Intergroup phase III trial

E. Eisenhauer, I. Vergote, G. Kristensen, 2002 .

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

M. Piccart, K. Swenerton, B. Zee, 2000, Journal of the National Cancer Institute.

Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)

Dong Liang, Brooke L. Fridley, Jennifer A. Doherty, 2015, Journal of genetics and genome research.

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

E. Trimble, M. Parmar, E. Eisenhauer, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data

I. Vergote, J. Canon, Y. Humblet, 2005 .

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.

I. Vergote, S. Pignata, I. Ray-Coquard, 2020, JAMA oncology.

Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

I. Vergote, J. Rau, A. Cardona, 2019, International Journal of Gynecological Cancer.

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

Cesar M. Castro, M. Birrer, I. Vergote, 2020, Gynecologic oncology.

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells

E. Berns, A. W. Boersma, E. Wiemer, 2013, Oncogene.

Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer.

I Vergote, H E Danielsen, V. Abeler, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Regional differences in therapy and clinical management of endometrial cancer: Findings of an international survey by the North-eastern German Society of Gynaecological Oncology (NOGGO).

I. Vergote, W. Lichtenegger, D. Miller, 2013 .

Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer

T. Bourne, B. van Calster, D. Timmerman, 2022, npj Genomic Medicine.

Mesonephric Carcinoma of the Ovary: A Report of Two Cases

I. Vergote, P. Moerman, Eveline Lurquin, 2015 .

Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models

D. Timmerman, D. Lambrechts, I. Vergote, 2020, Stem cell reports.

miR‐181a overexpression predicts the poor treatment response and early‐progression of serous ovarian cancer patients

A. Scorilas, E. Obermayr, R. Zeillinger, 2020, International journal of cancer.

Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

P. Neven, C. Desmedt, A. Salomon, 2020, Journal of the National Cancer Institute.

Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature

L. Lagae, I. Vergote, F. Amant, 2004, International Journal of Gynecologic Cancer.

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

F. Hirsch, I. Vergote, T. Macarulla, 2023, Cancers.

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.

A. Reuss, P. Hillemanns, F. Guyon, 2021, The New England journal of medicine.

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).

I. Vergote, I. Ray-Coquard, I. Benjamin, 2021, Gynecologic oncology.

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.

B. Monk, A. Oza, H. Hirte, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

B. Monk, A. Oza, I. Vergote, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

A. Reuss, A. Oza, A. Okamoto, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

A. Reuss, B. Weber, I. Vergote, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

M. Franchi, I. Vergote, A. Poveda, 2008, European journal of cancer.

Laser excision of the transformation zone as treatment of cervical intraepithelial neoplasia with satisfactory colposcopy.

I. Vergote, A. Makar, K. Kjørstad, 1992, Gynecologic oncology.

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium

R. Zeillinger, I. Vergote, N. Concin, 2014, OncoTargets and therapy.

Should we screen for endometrial cancer?

D. Timmerman, I. Vergote, F. Amant, 2011, The Lancet. Oncology.

Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis

I. Vergote, F. Amant, P. Moerman, 2004, International Journal of Gynecologic Cancer.

Joint ENGOT and GOG Foundation requirements for trials with industry partners

I. Vergote, S. Pignata, R. Coleman, 2019, International Journal of Gynecological Cancer.

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

B Richter, I Vergote, V. Gebski, 2011, British Journal of Cancer.

Timing of debulking surgery in advanced ovarian cancer

I Vergote, K Leunen, P. Neven, 2008, International Journal of Gynecologic Cancer.

Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer

A. Schneeweiss, P. Altevogt, C. Sohn, 2012, International journal of cancer.

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.

M. Birrer, I. Vergote, U. Matulonis, 2015, Gynecologic oncology.

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium

G. Heinze, E. Obermayr, D. Tong, 2013, BMC Cancer.

Absence of correlation between risk factors for endometrial cancer and the presence of tamoxifen-associated endometrial polyps in postmenopausal patients with breast cancer.

D. Timmerman, I. Vergote, J. Deprest, 2000, European journal of cancer.

Endocrine treatment and prevention of breast and gynaecological cancers.

P. Neven, W. Tjalma, I. Vergote, 2004, European journal of cancer.

Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen‐treated women

D. Timmerman, P. Neven, I. Vergote, 2003, Cancer.

Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer--Gynecological Cancer Group (EORTC-GCG).

I. Vergote, P. Ottevanger, N. Reed, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay.

T. Bourne, B. van Calster, D. Timmerman, 2011, Obstetrics and gynecology.

Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.

I. Vergote, I. Ray-Coquard, F. Heitz, 2022, Journal of Clinical Oncology.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Aromatase Inhibitors in Premenopausal Women: The Need for Proper Contraceptive Counseling

P. Neven, R. Paridaens, M. Christiaens, 2006, The breast journal.

Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study.

P. Hillemanns, I. Vergote, G. Scambia, 2020, European journal of cancer.

Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.

P. Neven, D. Lambrechts, I. Vergote, 2022, Gynecologic oncology.

Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.

B. van Calster, D. Timmerman, P. Neven, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis

I. Vergote, S. Darb-Esfahani, N. Concin, 2021, International Journal of Gynecological Cancer.

LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial.

A. Reuss, R. Kimmig, I. Vergote, 2017 .

Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk

Dong Liang, Brooke L. Fridley, Jennifer A. Doherty, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Dennis J. Hazelett, 2017, Nature Genetics.

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

Brooke L. Fridley, Matthias W. Beckmann, Peter A. Fasching, 2013, Nature Genetics.

A case report of unusual complication of myomatous uterus in pregnancy: spontaneous perforation of myoma after red degeneration.

I. Vergote, E. Schatteman, L. Meeuwis, 1989, European journal of obstetrics, gynecology, and reproductive biology.

Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.

E. Obermayr, R. Zeillinger, I. Vergote, 2013, Gynecologic oncology.

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

D. Matei, I. Vergote, S. Kaye, 2009, European journal of cancer.

Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.

B. van Calster, V. Van Belle, P. Neven, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive

S. Huffel, N. Pochet, D. Timmerman, 2008, Breast Cancer Research and Treatment.

Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium.

R. Zeillinger, I. Vergote, C. Lamina, 2013, Gynecologic oncology.

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.

B. Monk, R. Wenham, H. Gabra, 2023, Gynecologic oncology.

Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

I. Vergote, L. Dirix, H. Denys, 2022, International Journal of Gynecological Cancer.

Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer

I. Vergote, N. Concin, Sileny N. Han, 2021, International Journal of Gynecological Cancer.

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.

B. Monk, I. Vergote, S. Pignata, 2021, The Lancet. Oncology.

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

D. Provencher, M. Birrer, I. Vergote, 2019, Gynecologic oncology.

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

I. Vergote, H. Ulmer, I. Ray-Coquard, 2019, Front. Oncol..

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

C. Denkert, I. Vergote, S. Darb-Esfahani, 2019, Journal of Cancer Research and Clinical Oncology.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

B. Monk, B. van Calster, R. Wenham, 2019, The Lancet. Oncology.

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.

M. Birrer, I. Vergote, D. O’Malley, 2018, Gynecologic oncology.

The feasibility of open laparoscopy in gynecologic-oncologic patients.

I. Vergote, P. Berteloot, J. Decloedt, 1997, Gynecologic oncology.

Immunological parameters as a new lead in the diagnosis of ovarian cancer

D. Timmerman, I. Vergote, A. Coosemans, 2015, Facts, views & vision in ObGyn.

Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2015, Gynecologic oncology.

Evaluation of 211At-labelled monodisperse polymer particles in vivo : Comparison of different specific activities

I. Vergote, K. Nustad, R. Larsen, 1996 .

B-cell hybridoma as intraperitoneal tumor model: correlation between tumor growth and monoclonal antibody production.

J. Nesland, I. Vergote, K. Nustad, 1992, Hybridoma.

Para-aortic lymph node surgical staging in locally-advanced cervical cancer: comparison between robotic versus conventional laparoscopy

I. Vergote, N. Concin, T. Van Gorp, 2020, International Journal of Gynecological Cancer.

Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study.

A. Whittemore, L. Kiemeney, M. Beckmann, 2016, International journal of epidemiology.

Mendelian randomization Association of vitamin D levels and risk of ovarian cancer : a Mendelian randomization study

A. Whittemore, L. Kiemeney, M. Beckmann, 2016 .

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

H. Gabra, I. Vergote, S. Darb-Esfahani, 2017, European journal of cancer.

Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study.

T. Bourne, B. van Calster, D. Timmerman, 2019, The Lancet. Oncology.

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

M. van Glabbeke, M. Piccart, D. Lacombe, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.

M. Beckmann, P. Fasching, R. Vierkant, 2013, Gynecologic oncology.

Prostaglandin F2 alpha in benign and malignant breast tumours.

I. Vergote, A. Herman, G. Laekeman, 1985, British Journal of Cancer.

Type of chemotherapy has substantial effects on the immune system in ovarian cancer

I. Vergote, A. Coosemans, J. Ceusters, 2021, Translational oncology.

Increased expression of placental growth factor in high-grade endometrial carcinoma

I. Vergote, F. Amant, L. Coenegrachts, 2012, Oncology reports.

Predicting the clinical behavior of ovarian cancer from gene expression profiles

D Timmerman, N. Pochet, B. De Moor, 2005, International Journal of Gynecologic Cancer.

Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age

B. Moor, N. Pochet, D. Timmerman, 2007, Breast Cancer Research and Treatment.

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer

M. Beckmann, P. Fasching, T. Sellers, 2016, Oncotarget.

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2018, PloS one.

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.

A. Spurdle, D. Lambrechts, J. Marcickiewicz, 2013, Gynecologic oncology.

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.

K. Rhodes, I. Vergote, I. Ray-Coquard, 2021, European journal of cancer.

Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer

Sebastian M. Armasu, M. Beckmann, P. Fasching, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer

Yurii B. Shvetsov, Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, 2016, Oncotarget.

Strong vaccine responses during chemotherapy are associated with prolonged cancer survival

S. H. van der Burg, G. Kenter, M. Welters, 2020, Science Translational Medicine.

Robotic retroperitoneal lower para‐aortic lymphadenectomy in cervical carcinoma: First report on the technique used in 5 patients

P. Neven, I. Vergote, F. Amant, 2008, Acta obstetricia et gynecologica Scandinavica.

ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).

A. Oza, R. Wenham, H. Gabra, 2018 .

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

I. Vergote, G. Scambia, D. Dizon, 2015, Gynecologic oncology.

Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC).

B. Monk, I. Vergote, J. Sehouli, 2022, Journal of Clinical Oncology.

Survival with Cemiplimab in Recurrent Cervical Cancer.

B. Monk, Chih-Long Chang, S. Lheureux, 2022, The New England journal of medicine.

Second-line lenvatinib in patients with recurrent endometrial cancer.

I. Vergote, D. Miller, Y. Funahashi, 2020, Gynecologic oncology.

New models to predict depth of infiltration in endometrial carcinoma based on transvaginal sonography

N. Pochet, B. De Moor, D. Timmerman, 2006, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership

J. Ledermann, R. Glasspool, I. Vergote, 2015, International Journal of Gynecologic Cancer.

Management of Surgical Stage III and IV Endometrioid Endometrial Carcinoma: An Overview

I. Vergote, C. Burger, M. van der Burg, 2009, International Journal of Gynecologic Cancer.

Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.

J. Gostner, D. Fuchs, E. Obermayr, 2018, Gynecologic oncology.

Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial.

J. Seoane, I. Vergote, R. Verheijen, 2011, European journal of cancer.

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

D. Alberts, M. Parmar, V. Torri, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Retrospective Analysis of Outcome of Patients with Metastatic Leiomyosarcoma in a Tertiary Referral Center

R. Sciot, I. Vergote, M. Debiec‐Rychter, 2018, Oncology Research and Treatment.

Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers.

E. van Limbergen, P. Neven, R. Paridaens, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.

B. Monk, I. Vergote, S. Pignata, 2022, Journal of Clinical Oncology.

European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery

I. Vergote, C. Sessa, I. Ray-Coquard, 2016, International Journal of Gynecologic Cancer.

D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study

M. Piccart, M. Nooij, M. Namer, 2001, Anti-cancer drugs.

Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma

P. Neven, I. Vergote, F. Amant, 2009, International Journal of Gynecologic Cancer.

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer.

R. Rouzier, I. Vergote, F. Landoni, 2017, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis

F. Guyon, I. Vergote, A. Papanikolaou, 2020, Archives of Gynecology and Obstetrics.

The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.

Ignace Vergote, Andreas Scorilas, Marco Massobrio, 2003, Cancer research.

Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26-28, 2006.

P. Neven, I. Vergote, F. Amant, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Treatment algorithm in patients with ovarian cancer

K. K. van de Vijver, I. Vergote, H. Denys, 2020, Facts, views & vision in ObGyn.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study

C. Tournigand, A. Schneeweiss, C. Bokemeyer, 2014, Medical Oncology.

The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing

L. Kiemeney, M. Pike, M. Beckmann, 2011, Clinical Cancer Research.

Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer

S. Huffel, D. Timmerman, P. Neven, 2008, Breast Cancer Research and Treatment.

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

M. Ellis, A. Howell, J. Robertson, 2003, Cancer.

Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

B. Monk, A. Oza, I. Vergote, 2021 .

Antiangiogenic therapies in ovarian cancer

I. Vergote, A. Vanderstichele, S. Olbrecht, 2018, memo - Magazine of European Medical Oncology.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

B. Monk, A. Oza, R. Wenham, 2017, European journal of cancer.

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

B. Karlan, A. Oza, D. Provencher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A PHASE 1B STUDY OF AMG 386 PLUS PACLITAXEL AND CARBOPLATIN IN OVARIAN CANCER PATIENTS UNDERGOING PRIMARY OR INTERVAL DEBULKING SURGERY

I. Vergote, Benjamin Wu, M. Puhlmann, 2012 .

Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome

I. Vergote, C. Verslype, A. Laenen, 2016, Radiology and oncology.

Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2016, International journal of epidemiology.

Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.

P. Neven, I. Vergote, H. Brems, 2020, Gynecologic oncology.

Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.

I Vergote, I. Vergote, P Abram, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

A. Oza, J. Ledermann, T. Park-Simon, 2020 .

Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994.

D. Katsaros, G. Kenter, I. Vergote, 2019, Journal of Clinical Oncology.

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

C. Schade-Brittinger, F. Marmé, I. Vergote, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

A. Whittemore, L. Kiemeney, M. Pike, 2015, Nature Communications.

Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors

B. van Calster, D. Timmerman, P. Neven, 2019, International Journal of Gynecological Cancer.

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer

C. Denkert, J. Budczies, S. Wienert, 2018, Neoplasia.

The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer.

I. Vergote, A. Coosemans, G. Verbist, 2016, Anticancer research.

Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study

I. Vergote, H. Gerhardt, A. Coosemans, 2020, Cells.

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

D. Matei, J. Ledermann, C. Scott, 2018, British Journal of Cancer.

Novel therapies, including enzastaurin, in the treatment of ovarian cancer

I. Vergote, 2014, Expert opinion on investigational drugs.

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

David C. Smith, R. Berger, R. Kurzrock, 2017, European journal of cancer.

Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci

M. Beckmann, P. Fasching, E. Goode, 2017, Oncotarget.

Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci.

M. Beckmann, P. Fasching, E. Goode, 2017, Oncotarget.

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium

G. Heinze, C. Denkert, R. Zeillinger, 2013, BMC Cancer.

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm

D Timmerman, I Vergote, B De Moor, 2011, British Journal of Cancer.

Statistical controversies in clinical research: the importance of importance.

M. Schemper, R. Zeillinger, I. Vergote, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival.

G. Kenter, M. Welters, C. Melief, 2017 .

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns

T. Dickhaus, M. T. Hasan, E. Berns, 2013, Epigenetics.

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.

M. Birrer, I. Vergote, U. Matulonis, 2018, Future oncology.

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer

G. Heinze, P. Zimmermann, M. Jaritz, 2019, Computational and structural biotechnology journal.

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications

I. Vergote, R. Coleman, C. Marth, 2015, Cancer and Metastasis Reviews.

Ovarian cancer in children and adolescents: A rare disease that needs more attention.

I. Vergote, A. Coosemans, A. Uyttebroeck, 2016, Maturitas.

rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2018, International journal of molecular sciences.

Human K allikrein 6 ( hK6): A N ew P otential S erum B iomarker for D iagnosis a nd P rognosis o f O varian C arcinoma

D. Katsaros, G. Yousef, A. Scorilas, 2003 .

Human Kal l ikre in 6 ( hK 6 ) : A New Potent ia l Serum Biomarker for Diagnosis and Prognosis of Ovar ian Carc inoma

D. Katsaros, G. Yousef, A. Scorilas, 2003 .

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.

R. Zeillinger, I. Vergote, H. Ulmer, 2013, Gynecologic oncology.

Ovarian cancer prediction in adnexal masses using ultrasound‐based logistic regression models: a temporal and external validation study by the IOTA group

S Van Huffel, D Timmerman, I Vergote, 2010, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome

A. Whittemore, M. Pike, M. Beckmann, 2013, Cancer Epidemiology, Biomarkers & Prevention.

Application of proteomics in ovarian cancer: which sample should be used?

D. Timmerman, I. Vergote, F. Amant, 2009, Gynecologic oncology.

Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women

Jack A. Taylor, A. Whittemore, L. Kiemeney, 2019, Cancer medicine.

3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration.

E. Trimble, M. Parmar, E. Eisenhauer, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Balancing false positives and false negatives for the detection of differential expression in malignancies

F De Smet, Y Moreau, K Engelen, 2004, British Journal of Cancer.

Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?

P. Neven, M. Christiaens, I. Vergote, 2008, Breast Cancer Research and Treatment.

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

F. Guyon, I. Vergote, I. Ray-Coquard, 2023, Bulletin du Cancer.

Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer

P. Neven, H. Wildiers, G. Floris, 2020, Breast Cancer Research and Treatment.

Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy

P. Neven, C. Desmedt, H. Wildiers, 2019, Breast Cancer Research and Treatment.

Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.

I. Vergote, J. Sehouli, H. Kulbe, 2022, Gynecologic Oncology.

Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer

D. Timmerman, L. Boon, P. Agostinis, 2021, Journal for ImmunoTherapy of Cancer.

Lymphoedema Functioning, Disability and Health Questionnaire for Lower Limb Lymphoedema (Lymph-ICF-LL): Reliability and Validity

I. Vergote, R. Damstra, M. Van Kampen, 2014, Physical Therapy.

Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study

E. Obermayr, R. Zeillinger, I. Vergote, 2022, Cancers.

Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

M. Friedlander, I. Vergote, M. Jedryka, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

T2-weighted MR imaging of the uterus: comparison of optimized fast spin-echo and HASTE sequences with conventional fast spin-echo sequences.

A L Baert, H Bosmans, I Vergote, 1998, AJR. American journal of roentgenology.

Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.

V. Abeler, I. Vergote, G. Tulunay, 2004, Gynecologic oncology.

Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

S. Loibl, N. Burchardi, I. Vergote, 2007 .

Abstracts from the 4th ImmunoTherapy of Cancer Conference

R. Rees, F. Regnier, A. Trautmann, 2017, Journal of Immunotherapy for Cancer.

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium

D. Timmerman, I. Vergote, J. Sehouli, 2014, Journal of Ovarian Research.

Is it safe to treat endometrial carcinoma endoscopically?

P. Neven, I. Vergote, F. Amant, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EORTC-GCG process quality indicators for ovarian cancer surgery.

I. Vergote, P. Ottevanger, L. Verleye, 2009, European journal of cancer.

Ten years of live surgical broadcast at Charité-MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome

S. Kuemmel, I. Vergote, W. Cliby, 2022, International Journal of Gynecological Cancer.

Prophylactic oophorectomy at hysterectomy for benign pathology

I. Vergote, P. Buytaert, 1984 .

Is there a role for HIPEC in ovarian cancer?

I. Vergote, J. Sehouli, L. Chiva, 2018, Archives of Gynecology and Obstetrics.

Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – final analysis of AGO DESKTOP III/ENGOT- ov20

A. Reuss, F. Guyon, I. Vergote, 2020, Geburtshilfe und Frauenheilkunde.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

A. Reuss, I. Vergote, S. Pignata, 2016, The Lancet. Oncology.

Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update

I. Vergote, N. Concin, P. Morice, 2020, International Journal of Gynecological Cancer.

Multi‐center experience of robot‐assisted laparoscopic para‐aortic lymphadenectomy for staging of locally advanced cervical carcinoma

Karin Leunen, Ignace Vergote, Frédéric Goffin, 2013, Acta obstetricia et gynecologica Scandinavica.

Psychological impact of endometrial monitoring in tamoxifen-treated postmenopausal breast cancer patients

T. Bourne, D. Timmerman, K. Demyttenaere, 2000, Journal of psychosomatic obstetrics and gynaecology.

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium

E. Obermayr, R. Zeillinger, I. Vergote, 2021, Cancers.

D. Matei, J. Ledermann, C. Scott, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery

I. Vergote, I. Ray-Coquard, B. Davidson, 2017, International Journal of Gynecologic Cancer.

Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group

Sabine Van Huffel, Dirk Timmerman, Ignace Vergote, 2010, BMJ : British Medical Journal.

The tumor suppressor protein PTEN undergoes amyloid-like aggregation in tumor cells

D. Lambrechts, K. Nilsson, I. Vergote, 2020, bioRxiv.

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.

I. Vergote, C. Sessa, N. Concin, 2018, Gynecologic oncology.

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

P. V. van Dam, W. Tjalma, I. Vergote, 1998, Gynecologic oncology.

A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.

T. Bourne, B. van Calster, D. Timmerman, 2013, Gynecologic oncology.

Flow Cytometry in Invasive Endometrial Carcinoma

I. Vergote, C. Tropé, J. Kærn, 1991 .

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group

I. Vergote, I. Ray-Coquard, P. Harter, 2012, British Journal of Cancer.

HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma

T. Agorastos, I. Vergote, I. Kalogiannidis, 2014, Archives of Gynecology and Obstetrics.

Leaders A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG

E. Berns, I. Vergote, S. Henzen‐Logmans, 2022 .

Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV)

I. Vergote, J. Sehouli, F. Joly, 2020, International Journal of Gynecological Cancer.

Expression III: What do primary and recurrent ovarian cancer (OC) patients expect from their doctors and therapy management? Results of a survey in eight European countries with 1,743 patients (NOGGO/ENGOT-OV9 study).

I. Vergote, S. Pignata, M. Jedryka, 2013 .

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.

L. Seymour, M. Brundage, H. Hirte, 2006, Gynecologic oncology.

Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer

V. Abeler, I. Vergote, C. Tropé, 1992, Cancer.

Prognostic Value of Serum HE4 Levels and Risk of Ovarian Malignancy Algorithm Scores at the Time of Ovarian Cancer Diagnosis

T. Bourne, B. van Calster, V. Van Belle, 2014, International Journal of Gynecologic Cancer.

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers

H. Mackay, A. Oza, R. Plummer, 2017, Targeted Oncology.

Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.

E. van Limbergen, A. Giobbie-Hurder, B. van Calster, 2018, The oncologist.

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Y. Drew, J. Machiels, Melissa L. Johnson, 2019, Clinical Cancer Research.

A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.

S. Wong, I. Vergote, J. Baurain, 2014, European journal of cancer.

Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group).

I. Vergote, P. Witteveen, C. Coens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.

I. Vergote, C. Tropé, M. Scheistrøen, 1992 .

Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II

D. Provencher, D. Cruickshank, M. Widschwendter, 2019, International Journal of Gynecological Cancer.

Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.

I. Soubeyran, I. Vergote, N. Sevenet, 2020, Journal of the National Cancer Institute.

Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers

P. Neven, I. Vergote, T. Juhler-Nøttrup, 2016 .

In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol.

P. Agostinis, I. Vergote, A. Coosemans, 2016, Anticancer research.

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium

C. Denkert, R. Zeillinger, I. Vergote, 2014, Molecular Cancer.

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

H. Gabra, I. Vergote, S. Darb-Esfahani, 2018, British Journal of Cancer.

Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter

E. Obermayr, R. Zeillinger, I. Vergote, 2018, International Journal of Gynecologic Cancer.

ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours

T. Bourne, I. Vergote, N. Concin, 2021, Facts, views & vision in ObGyn.

Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.

T. Bourne, B. van Calster, D. Timmerman, 2020, Gynecologic oncology.

The LACC Trial and Minimally Invasive Surgery in Cervical Cancer.

R. Kimmig, I. Vergote, M. Canis, 2020, Journal of minimally invasive gynecology.

Safety and efficiency of performing transvaginal ultrasound-guided tru-cut biopsy for pelvic masses.

D. Timmerman, T. Van den Bosch, I. Vergote, 2021, Gynecologic oncology.

ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

T. Bourne, D. Timmerman, I. Vergote, 2021, International Journal of Gynecological Cancer.

miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.

A. Scorilas, E. Obermayr, R. Zeillinger, 2020, Carcinogenesis.

A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

B. Monk, I. Vergote, R. Coleman, 2016 .

Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?

I. Vergote, I. Ray-Coquard, D. Cibula, 2023, Expert opinion on investigational drugs.

Prospective study of uterine sonographic changes after 3 months endocrine treatment in postmenopausal breast cancer patients: tamoxifen is estrogenic while aromatase inhibitors induce atrophy and can reverse the effect of tamoxifen

S. Huffel, D. Timmerman, P. Neven, 2003 .

Menopausal symptoms and uterine changes in postmenopausal breast cancer patients receiving tamoxifen or third generation aromatase inhibitors

S. Huffel, D. Timmerman, P. Neven, 2004 .

Prospective study on the effect of endocrine treatments on menopausal symptoms in breast cancer patients

S. Huffel, D. Timmerman, P. Neven, 2003 .

Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.

M. Nooij, M. Namer, I. Vergote, 2001, Gynecologic oncology.

Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial.

P. Bossuyt, G. Kenter, B. Mol, 2013, European journal of cancer.

Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.

P. Neven, P. V. van Dam, M. Christiaens, 2014, Breast.

P8 Screening for a geriatric risk profile in older cancer patients: a comparative study of the predictive validity of three screening tools

H. Wildiers, I. Vergote, J. Vansteenkiste, 2009 .

CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer

J. Ledermann, I. Vergote, R. Mathijssen, 2023, International Journal of Gynecological Cancer.

Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial.

P. Neven, M. Christiaens, I. Vergote, 2018, Journal of physiotherapy.

Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer

P. Neven, H. Wildiers, I. Vergote, 2018, Breast Cancer Research and Treatment.

Management of malignant ovarian immature teratoma. Role of adriamycin

V. Abeler, I. Vergote, C. Tropé, 1990, Cancer.

Neoadjuvant chemotherapy for ovarian cancer.

P. Neven, I. Vergote, F. Amant, 2005, Oncology.

Reproducibility of lymphoscintigraphic evaluation of the upper limb.

P. Neven, M. Christiaens, I. Vergote, 2014, Lymphatic research and biology.

Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer

P. Neven, D. Lambrechts, I. Vergote, 2020 .

Lymph Node Sampling and Taking of Blind Biopsies Are Important Elements of the Surgical Staging of Early Ovarian Cancer

I. Vergote, C. Coens, P. Timmers, 2010, International Journal of Gynecologic Cancer.

Safety and dose modification for patients receiving niraparib.

J. Berek, I. Vergote, S. Ellard, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses

S. Huffel, T. Bourne, B. van Calster, 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

G. Rustin, I. Vergote, L. Dirix, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial

I. Vergote, I. Ray-Coquard, G. Scambia, 2020, Oral Plenary.

Prostacyclin, thromboxane and prostaglandin F2 alpha; plasma levels in breast cancer.

I. Vergote, A. Herman, G. Laekeman, 1986, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.

B. Weber, I. Vergote, J. Šufliarský, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

965PEvaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)

A. Oza, C. Scott, I. Vergote, 2017 .

A Novel Approach to Predict the Likelihood of Specific Ovarian Tumor Pathology Based on Serum CA-125: A Multicenter Observational Study

T. Bourne, B. van Calster, D. Timmerman, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.

M. Aapro, M. Namer, I. Vergote, 2003, European journal of cancer.

V. Gebski, I. Vergote, S. Pignata, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.

P. Neven, D. Lambrechts, I. Vergote, 2019, Journal of Clinical Oncology.

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

T. Park-Simon, I. Vergote, I. Ray-Coquard, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Using artificial neural networks to predict malignancy of ovarian tumors

D. Timmerman, S. Van Huffel, C. Lu, 2001, 2001 Conference Proceedings of the 23rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

Reply: The performance of the risk of ovarian malignancy algorithm

D. Timmerman, I. Vergote, T. Van Gorp, 2011, British Journal of Cancer.

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.

Cesar M. Castro, M. Birrer, I. Vergote, 2019, Journal of Clinical Oncology.

A scoring system to differentiate malignant from benign masses in specific ultrasound‐based subgroups of adnexal tumors

T. Bourne, D. Timmerman, L. Valentin, 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

B. Monk, L. Kasten, A. Schlicker, 2022, International Journal of Gynecological Cancer.

LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial

F. Marmé, K. Yonemori, I. Vergote, 2020 .

Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort

T. Bourne, B. van Calster, D. Timmerman, 2022, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Patterns of care in surgery for ovarian cancer in Europe.

I. Vergote, A. van der Zee, L. Verleye, 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Surgical program building in advanced ovarian cancer: European perspective.

I. Vergote, P. Ottevanger, I. Vergote, 2009, Gynecologic oncology.

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

M. Tiemann, I. Vergote, Eva-Maria Willing, 2023, Cancers.

PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.

I. Vergote, S. Pignata, I. Ray-Coquard, 2016 .

PLATINUM COMBINATION CHEMOTHERAPY VERSUS PLATINUM MONOTHERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A META-ANALYSIS OF RANDOMISED TRIALS USING INDIVIDUAL PATIENT DATA (IPD)

D. Alberts, M. Parmar, J. Ledermann, 2012 .

A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes.

I. Vergote, T. Pintér, Y. Funahashi, 2013 .

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

C. Denkert, D. Tong, R. Zeillinger, 2012, Molecular Cancer.

Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.

B. Monk, Chun-Fang Xu, T. Johnson, 2014 .

Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.

I. Vergote, H. V. van Doorn, W. Onstenk, 2013, European journal of cancer.

Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.

R. Zeillinger, I. Vergote, N. Concin, 2013, Gynecologic oncology.

INTRAPERITONEAL (IP) CISPLATIN (P) VERSUS NO FURTHER TREATMENT: 8 YEAR-RESULTS OF AN EORTCGCG RANDOMIZED PHASE III STUDY IN OVARIAN CANCER (O.C.) PATIENTS (PTS) WITH A PATHOLOGICALLY COMPLETE REMISSION (PCR) AFTER P-BASED INDUCTION CHEMOTHERAPY (CT) AND CYTOREDUCTIVE SURGERY

M. Piccart, I. Vergote, P. Willemse, 2003, International Journal of Gynecologic Cancer.

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer

G. Heinze, P. Zimmermann, M. Jaritz, 2016, BMC Genomics.

Bayesian networks in ovarian cancer diagnosis: potentials and limitations

Sabine Van Huffel, Bart De Moor, Dirk Timmerman, 2000, Proceedings 13th IEEE Symposium on Computer-Based Medical Systems. CBMS 2000.

Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium

G. Heinze, R. Bast, E. Obermayr, 2023, Oncogene.

Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study.

D. Timmerman, I. Vergote, F. Amant, 2016, European journal of cancer.

Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers.

E. van Limbergen, P. Neven, E. Kellen, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.

B. Monk, I. Vergote, M. Mirza, 2023, European journal of cancer.

INNOVATE: A phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian cancer—Updated safety and efficacy results.

I. Vergote, C. Sessa, L. Manso, 2017 .

GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817).

S. Ramalingam, I. Vergote, Juanita Lopez, 2017 .

Laser excision of the transformation zone as treatment of cervical intraepithelial neoplasia with satisfactory colposcopy

I. Vergote, A. Makar, K. Kjørstad, 1992 .

P3-14-22: Response to Neoadjuvant Chemotherapy in Elderly Patients with Locally Advanced Breast Cancer.

P. Neven, R. Paridaens, M. Christiaens, 2011 .

A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer.

R. Bast, E. Fung, D. Chan, 2006, Journal of Clinical Oncology.

Transition of endometrial stromal sarcoma into high-grade sarcoma.

P. Neven, I. Vergote, F. Amant, 2006, Gynecologic oncology.

Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.

N. Pochet, P. Neven, R. Paridaens, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial

C. Genestie, I. Vergote, I. Ray-Coquard, 2022, Ovarian cancer.

2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial

M. Tiemann, I. Vergote, Eva-Maria Willing, 2022, Pathology.

ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

R. Wenham, S. Lheureux, I. Vergote, 2019, Journal of Clinical Oncology.

Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: Analysis of PAOLA-1/ENGOT-ov25 phase III trial.

K. Yonemori, I. Vergote, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

Additional Value of PET–CT in Staging of Clinical Stage IIB and III Breast Cancer

P. Neven, F. Mottaghy, R. Paridaens, 2010, The breast journal.

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.

B. Monk, S. Lheureux, I. Vergote, 2018 .

Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC).

I. Vergote, M. Jones, P. Rose, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer.

E. Lengyel, I. Vergote, R. Schilder, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.

Tuan S. Nguyen, T. Bauknecht, I. Vergote, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.

G. MacBeath, H. Hirte, I. Vergote, 2014 .

Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer

Hannah Yang, James Paul, Honglin Song, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Variation in NFk B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer

Brooke, Tanja, David N. Rider, 2014 .

Diagnosing adnexal tumours before surgery: a critical appraisal of recent evidence

T. Bourne, B. van Calster, D. Timmerman, 2015 .

Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?

T. Bourne, D. Timmerman, I. Vergote, 2014, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumors using biomarkers or the ROMA algorithm.

T. Bourne, D. Timmerman, I. Vergote, 2013, Gynecologic oncology.

Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines

Sabine Van Huffel, Johan A. K. Suykens, Dirk Timmerman, 2003, Artif. Intell. Medicine.

Postoperative Vaginal Irradiation by High-Dose-Rate Cobalt Afterloading in Stage I Endometrial Cancer: Experience from the Norwegian Radium Hospital

V. Abeler, I. Vergote, K. Kjørstad, 1991 .

Clinical management of ovarian cancer

I. Vergote, S. Kaye, W. Hoskins, 2001 .

941TiPENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER.

B. Monk, A. Oza, R. Wenham, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma

C. Genestie, I. Vergote, I. Ray-Coquard, 2022, medRxiv.

Bowel obstruction in advanced tubo-ovarian cancer: a retrospective cohort study

P. Neven, I. Vergote, A. Wolthuis, 2023, Annals of medicine and surgery.

Reporting on the results of cancer treatment in patients with metastatic liver disease: proposal of symmetric size-dependent CT-criteria for response.

E. Van Cutsem, L. V. Van Hoe, I. Vergote, 1996, Annals of Oncology.

A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma.

I. Vergote, C. Tropé, G. Kristensen, 1995, European journal of cancer.

hiF 1 α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVcaD consortium

R. Zeillinger, I. Vergote, N. Concin, 2014 .

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

H. Gabra, I. Vergote, S. Darb-Esfahani, 2018, British Journal of Cancer.

Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Long-term follow-up confirms a survival advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2002 .

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Communications.

Genome-wide significant risk associations for mucinous ovarian carcinoma

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Genetics.

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

E. Eisenhauer, A. Oza, D. Provencher, 2010, Journal of the National Cancer Institute.

PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS

Jane E. Carpenter, Lara E Sucheston-Campbell, Ali Amin Al Olama, 2016 .

ESGO statement on cervical cancer vaccination: August 2007

I. Jacobs, I. Vergote, N. Colombo, 2007, International Journal of Gynecologic Cancer.

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

L. Kiemeney, A. Hein, E. Goode, 2023, Canadian journal of surgery. Journal canadien de chirurgie.

The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer

I. Vergote, A. Coosemans, R. Gijsbers, 2015, Journal of Immunotherapy for Cancer.

Randomized trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by th Nordic Ovarian Cancer Study Group (NOCOVA)

I. Vergote, C. Tropé, T. Högberg, 1997 .

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

D. Katsaros, L. Cavanna, I. Meinhold-Heerlein, 2023, British Journal of Cancer.

833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer

Cesar M. Castro, D. Provencher, I. Vergote, 2020 .

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study.

I. Vergote, D. O’Malley, U. Matulonis, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovaria

M. Birrer, I. Vergote, U. Matulonis, 2017 .

18/#499 Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis

M. Birrer, I. Vergote, Jiuzhou Wang, 2022, Featured Printed Posters (Poster Rounds with the Professors).

A randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED).

I. Vergote, R. Naumann, L. Gilbert, 2013 .

Advanced epithelial ovarian cancer: 1998 consensus statements.

M. Parmar, E. Eisenhauer, M. Gore, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

NEWS ON ULTRASONOGRAPHIC TECHNIQUES FOR PELVIC MALIGNANCIES

B. De Moor, D. Timmerman, S. Van Huffel, 2003, International Journal of Gynecologic Cancer.

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium

A. Whittemore, L. Kiemeney, M. Pike, 2015, Clinical Cancer Research.

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.

A. Reuss, P. Hillemanns, F. Guyon, 2022, The New England journal of medicine.

SUCCOR Nodes: May Sentinel Node Biopsy Determine the Need for Adjuvant Treatment?

P. Rolland, F. Guyon, B. Chiofalo, 2023, Annals of Surgical Oncology.

Supplementary Information for HOTAIR AND ITS SURROGATE DNA METHYLATION SIGNATURE INDICATE CARBOPLATIN RESISTANCE IN OVARIAN CANCER

Richard G. Jenner, B. Fridley, E. Goode, 2015 .

CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.

I. Vergote, I. Ray-Coquard, A. Nieto, 2016 .

Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer

J. Brenton, H. Gabra, I. Vergote, 2015 .

Importance of synovial fluid retention and tickening in patients with severe musculoskeletal pain treated with letrozole or exemstance: a case series describing the impact of symptoms, clinical findings and magnetic resonance imaging

D. Timmerman, P. Neven, R. Paridaens, 2006 .

Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second‐look laparotomy

I. Vergote, C. Tropé, M. Winderen, 1993, Cancer.

Genomic aberrations relate early and advanced stage ovarian cancer

P. V. van Diest, B. Ylstra, G. Meijer, 2012, Cellular Oncology.

Adjuvant treatment of ovarian carcinoma

I. Vergote, 1993 .

Biology and prognosis by age of primary operable breast cancer.

Patrick Neven, S. Van Huffel, Frédéric Amant, 2009 .

Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation

Olivier Gevaert, Dirk Timmerman, Kristof Engelen, 2008, BMC Cancer.

Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIG study of NCIC CTG, EORTC-GCG, and GEICO.

E. Eisenhauer, D. Provencher, M. Carey, 2013 .

Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers.

E. van Limbergen, P. Neven, E. Kellen, 2013 .

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS

Jane E. Carpenter, Lara E Sucheston-Campbell, A. Whittemore, 2016, Journal of Medical Genetics.

Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer

David N. Rider, A. Whittemore, M. Pike, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Using Bayesian neural networks with ARD input selection to detect malignant ovarian masses prior to surgery

Sabine Van Huffel, Dirk Timmerman, Ian T. Nabney, 2008, Neural Computing and Applications.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2015, Journal of genetics and genome research.

Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

D. Matei, J. Ledermann, C. Scott, 2015 .

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.

M. Parmar, E. Eisenhauer, G. Rustin, 2000, Journal of the National Cancer Institute.

I. Vergote, L. Gianni, G. Ross, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

J. Ledermann, I. Vergote, I. McNeish, 2019, International Journal of Gynecological Cancer.

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.

P. Neven, D. Lambrechts, I. Vergote, 2023, European journal of cancer.

Aflibercept (VEGF TRAP) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: results of a randomized, double-blind, placebo-controlled study

D. Provencher, H. Hirte, I. Vergote, 2009 .

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

A. Reuss, I. Vergote, S. Pignata, 2016, The Lancet. Oncology.

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium

A. Whittemore, L. Kiemeney, M. Pike, 2015, Clinical Cancer Research.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

H. Gabra, I. Vergote, S. Darb-Esfahani, 2017, European journal of cancer.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, Dennis J. Hazelett, 2014, Nature Genetics.

Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Management of Surgical Stage III and IV Endometrioid Endometrial Carcinoma: An Overview

I. Vergote, C. Burger, M. van der Burg, 2009, International Journal of Gynecologic Cancer.

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

I. Vergote, J. Sehouli, F. Joly, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.

B. Monk, I. Vergote, J. Sehouli, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

G. Kenter, M. Nankivell, S. Kehoe, 2018, The Lancet. Oncology.

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

E. Eisenhauer, G. Rustin, I. Vergote, 2005, Journal of the National Cancer Institute.

Classification of Ovarian Tumors Using Bayesian Least Squares Support Vector Machines

Sabine Van Huffel, Johan A. K. Suykens, Dirk Timmerman, 2003, AIME.

First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival

I. Vergote, M. Mirza, G. Stuart, 2004 .

Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.

T. Bourne, D. Timmerman, L. Valentin, 2016, American journal of obstetrics and gynecology.

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

B. Monk, A. Oza, I. Vergote, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma

P. Neven, I. Vergote, F. Amant, 2009, International Journal of Gynecologic Cancer.

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

M. Parmar, J. Ledermann, I. Vergote, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

A. Whittemore, L. Kiemeney, M. Pike, 2016, Cancer discovery.

Gestational choriocarcinoma

I. Vergote, S. Pignata, N. Concin, 2023, International Journal of Gynecological Cancer.

Lymphadenectomy in endometrial cancer

P. Neven, I. Vergote, F. Amant, 2009, The Lancet.

How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma.

I. Vergote, E. Van Nieuwenhuysen, A. Vanderstichele, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection

I. Vergote, S. Pignata, I. Treilleux, 2022, Ovarian cancer.

Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)

P. Neven, D. Lambrechts, I. Vergote, 2022, Gynecologic Oncology.

Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994

D. Katsaros, I. Vergote, F. Landoni, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

B. Monk, I. Vergote, M. Zikan, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving the preoperative classification of adnexal masses as benign or malignant by second‐stage tests

T. Bourne, D. Timmerman, L. Valentin, 2011, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer

A. Schneeweiss, P. Altevogt, C. Sohn, 2012, International journal of cancer.

Selinexor in patients with advanced and recurrent endometrial cancer.

B. Monk, I. Vergote, A. Mariani, 2023, Current problems in cancer.

I. Vergote, P. Witteveen, C. Coens, 2009, Annals of Oncology.

LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

B. Monk, I. Vergote, S. Pignata, 2020 .

First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.

I. Vergote, Juanita Lopez, F. Thistlethwaite, 2019, Journal of Clinical Oncology.

Hormone receptor expression in Flemish patients with in situ and invasive primary breast cancer

P. Neven, P. Dam, W. Tjalma, 2002 .

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.

I. Vergote, F. Amant, A. Laenen, 2015, Gynecologic oncology.

Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC).

I. Vergote, P. Schöffski, J. Delord, 2010 .

EP233/#541 Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-ov26/GOG-3012 post-hoc subgroup analysis

B. Monk, I. Vergote, M. Mirza, 2022, E-Posters.

Prostacyclin/thromboxane ratio in human breast cancer.

P. V. van Dam, I. Vergote, A. Herman, 1991, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.